Boston Common Asset Management LLC Has $16.41 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Boston Common Asset Management LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 25.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 227,564 shares of the medical equipment provider's stock after selling 79,101 shares during the period. Boston Common Asset Management LLC owned 0.10% of Hologic worth $16,405,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of HOLX. State Street Corp lifted its stake in Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock worth $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC lifted its position in shares of Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after buying an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock valued at $208,051,000 after buying an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Hologic by 8.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock valued at $200,952,000 after buying an additional 195,285 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Hologic by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock worth $172,780,000 after acquiring an additional 124,739 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Down 0.3 %

NASDAQ HOLX traded down $0.24 during trading on Friday, reaching $69.73. 6,395,054 shares of the company's stock were exchanged, compared to its average volume of 2,046,611. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a fifty-two week low of $68.61 and a fifty-two week high of $84.67. The company's fifty day simple moving average is $74.84 and its 200-day simple moving average is $78.34. The firm has a market capitalization of $15.82 billion, a PE ratio of 20.94, a P/E/G ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic's revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 EPS. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HOLX. Mizuho dropped their target price on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Royal Bank of Canada lifted their price objective on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a research report on Tuesday, November 5th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They issued a "peer perform" rating on the stock. Finally, StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $88.92.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.75% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.